Acasti Pharma Cmn A (ACST) 1.89 $ACST Acasti Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2016 at 9:00 AM

Acasti Pharma Cmn A (ACST) 1.89 $ACST

Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
Marketwire Canada - Wed Sep 14, 7:02AM CDT
Results Support Streamlined Regulatory Pathway for Novel Hypertriglyceridemia Drug
ACST: 1.89 (+0.01), NTB.TO: 1.39 (+0.07), NEPT: 1.05 (+0.05), APO.VN: 2.550 (+0.140)

Acasti Announces Grant of Stock Options
Marketwire Canada - Mon May 30, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 30, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"

(NASDAQ: ACST)(TSX VENTURE: APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16), AGN: 243.94 (+0.51), ABUS: 3.96 (+0.01), ACST: 1.89 (+0.01), AZN: 33.97 (-0.31), CBAY: 1.95 (+0.03)

Acasti incurs Q3 net loss of CAD2.191m
M2 - Wed Jan 13, 6:07AM CST
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) stated on Tuesday that it recorded a net loss of CAD2.191m for the third quarter ended 30 November 2015.
ACST: 1.89 (+0.01)

Acasti reports 3Q loss
Automated Insights - Tue Jan 12, 5:24PM CST
LAVAL, Quebec (AP) _ Acasti Pharma Inc. (ACST) on Tuesday reported a fiscal third-quarter loss of $1.7 million, after reporting a profit in the same period a year earlier.
ACST: 1.89 (+0.01)

Acasti Announces Third Quarter Results
GlobeNewswire - Tue Jan 12, 4:26PM CST
-- Important progress made with FDA on CaPre(R) development pathway
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti Provides Update on CaPre(R) Development Pathway
GlobeNewswire - Wed Dec 16, 6:50AM CST
-- Encouraging response from FDA on CaPre(R) clinical development
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
GlobeNewswire - Tue Dec 01, 6:30AM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"

(NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that the Japanese, Taiwanese and Mexican patent offices have each recently granted Acasti a composition and use patent (the "Patents"

.
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

TSX Venture Exchange Daily Bulletins
CNW Group - Wed Oct 14, 5:14PM CDT
TSX VENTURE COMPANIES
ACST: 1.89 (+0.01)

Acasti Announces Second Quarter Results
GlobeNewswire - Wed Oct 14, 4:10PM CDT
-- Important progress made in FDA discussions on development pathway for CaPre(R)
ACST: 1.89 (+0.01), APO.VN: 2.550 (+0.140)

Acasti approves one for ten reverse stock split
M2 - Wed Sep 30, 5:23AM CDT
Biopharmaceutical company Acasti Pharma (NasdaqCM:ACST) (TSXV:APO.V) declared on Tuesday that it will consolidate its issued and outstanding Class A common shares on the ratio of one post-consolidation common share for every ten pre-consolidation common shares provided each fractional common share shall be rounded up.
ACST: 1.89 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Citrine Finalizes Sale of Illinois Senior Living Asset

Citrine's Strategic Exit from River Glen Every now and then, you see a company pull off something that makes you nod and say, "That was smart." Citrine Investment Group's sale of River Glen of St. Charles fits that bill. For those keeping tabs, this wasn't some quick flip—Citrine worked on the rock for a good while before cashing in. They secured River Glen back in...

Orthopedic Expert Highlighting Midwest Pain Access Gaps

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

FC2 Condom Educates NYC on Health and Wellness

Union Square Becomes a Hub of Interactivity The heart of NYC pulsed with purpose as FC2 Female Condom set up shop in Union Square, using the iconic location as a stage for a different kind of celebration. Clear Future, the manufacturer behind FC2, marked Global Female Condom Day with an event unlike any other. It wasn't just about the product—it was a call to educate...

CSS Revamps Identity, Emphasizing Senior Living Tech

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Mutare Sharpens Security for Webex Calls with Precision

Control Dialed In: Tailored Call Screening Kicking things up a notch, Mutare is redefining call security by fine-tuning their Voice Security for Webex Calling. Imagine this—custom rules now let organizations shape a security policy down to the very last detail, ensuring unwanted calls don’t slip through the cracks. Wave goodbye to the broad-strokes approach. Precision...

NY Sheriffs' Court Battle: Immigration Policies Under Fire

Sheriffs Clash with State Over Immigration Policies In a tense showdown reminiscent of an old-time standoff, 15 New York county sheriffs have drawn their battle lines against the state’s capricious maneuvers by pushing a federal court to hit the brakes on Albany’s newly minted immigration rule. The so-called “Local Cops, Local Crimes Act” is catching serious heat,...

Robotics in Cleaning: 2026 Sees Double Adoption Rates

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

WellLink Advisory Board Eyes Future of Healthcare Innovation

Strategic Collaboration for Healthcare Evolution Ready to shake things up in healthcare, WellLink is setting the stage with its brand new Advisory Board. This move isn’t just about having fancy titles sitting around a conference table — it's about grabbing onto the future with both hands and figuring out just what the heck the healthcare industry needs next....

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Rosewood HK Tops Best Hotel List Again; Asia Shines

Holding the Crown: Rosewood Hong Kong's Triumph When a single hotel keeps nabbing the top spot in the world's most prestigious rankings, it's worth taking a closer look. That's exactly what's happening with Rosewood Hong Kong, crowned the world's best once more in 2026—its second consecutive year at the pinnacle according to The 50 Best Hotels. Defining Luxury on a...